Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $360.6667.

Several equities research analysts recently issued reports on the stock. Bank of America lifted their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. TD Cowen lifted their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Finally, HC Wainwright lifted their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a report on Tuesday, June 16th.

Insiders Place Their Bets

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 26,642 shares of company stock valued at $8,243,923. Insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KRYS. Hennion & Walsh Asset Management Inc. acquired a new position in Krystal Biotech during the second quarter worth about $337,000. GAMMA Investing LLC lifted its position in shares of Krystal Biotech by 16.3% in the 2nd quarter. GAMMA Investing LLC now owns 998 shares of the company’s stock valued at $371,000 after acquiring an additional 140 shares in the last quarter. Harbor Investment Advisory LLC acquired a new stake in shares of Krystal Biotech in the second quarter worth $92,000. Versant Capital Management Inc boosted its position in Krystal Biotech by 189.2% during the 2nd quarter. Versant Capital Management Inc now owns 214 shares of the company’s stock worth $80,000 after acquiring an additional 140 shares during the period. Finally, Pacer Advisors Inc. grew its position in Krystal Biotech by 48.8% during the first quarter. Pacer Advisors Inc. now owns 2,547 shares of the company’s stock valued at $658,000 after purchasing an additional 835 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

KRYS opened at $363.28 on Thursday. Krystal Biotech has a 12 month low of $130.50 and a 12 month high of $382.54. The business has a 50-day moving average of $337.61 and a two-hundred day moving average of $295.22. The stock has a market capitalization of $10.71 billion, a price-to-earnings ratio of 48.57 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The company had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. Equities research analysts anticipate that Krystal Biotech will post 7.31 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.